Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma

Nature Reviews Clinical Oncology

Volumn 7, Issue 5, 2010, Pages 289-294

  Ludwig, Heinz ^a   Zojer, Niklas ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPYRONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; NARCOTIC ANALGESIC AGENT; RECOMBINANT ERYTHROPOIETIN; ZOLEDRONIC ACID;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CD34 SELECTION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROPHORESIS; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; GAMMOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SPINE FRACTURE; THROMBOCYTOPENIA; URINALYSIS; URINARY EXCRETION; WEAKNESS; X RAY ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; X-RAYS;

EID: 77951880822     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.31     Document Type: Article

References (30)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Boyle, P. & Ferlay, J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481-488 (2005). (Pubitemid 40458328)
3. American Cancer Society. Detailed guide: multiple myeloma. What are the risk factors for multiple myeloma? Cancer Reference Information [online], http://www.cancer.org/docroot/CRI/content/CRI-2-4-2X-What-are-the-risk-factors- for-multiple-myeloma-30.asp (2010).
4. Kristinsson, S. Y. et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Hematologica 94, 1714-1720 (2009).
5. Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962-2972 (2008).
6. Dimopoulos, M. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23, 1545-1556 (2009).
7. Ludwig, H. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15, 6-25 (2010).
8. Eriksson, T. et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J. Pharm. Pharmacol. 55, 1701-1706 (2003). (Pubitemid 38054404)
9. Terpos, E., Roussou, M. & Dimopoulos, M. A. Bortezomib in multiple myeloma. Expert Opin. Drug Metab. Toxicol. 4, 639-654 (2008). (Pubitemid 351890744)
10. Chen, N. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47, 1466-1475 (2007). (Pubitemid 350115306)
11. Oakervee, H. E. et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Hematol. 129, 755-762 (2005). (Pubitemid 40904525)
12. Sterz, J. et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin. Investig. Drugs 17, 879-895 (2008). (Pubitemid 351864325)
13. Kastritis, E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasonecontaining regimens and the impact of novel agents. Hematologica 92, 546-549 (2007). (Pubitemid 350144300)
14. Ludwig, H. et al. Bortezomib-doxorubicindexamethasone (BDD) in patients with acute light chain induced renal failure (ARF) in multiple myeloma (MM). Final results of a phase II study [abstract 3862]. Blood 114, 1486a (2009).
15. Weber, D. et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract 3547]. Blood 108, 1012a (2006).
16. Weber, D. M. et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function [abstract 8542]. J. Clin. Oncol. 26 (Suppl.), 464s (2008).
17. ®) ± corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels [abstract 3548]. Blood 108, 1013a (2006).
18. Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133-2142 (2007). (Pubitemid 350146108)
19. Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123-2132 (2007). (Pubitemid 350146107)
20. Niesvizky, R. et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Hematol. 138, 640-643 (2007). (Pubitemid 47206719)
21. Dimopoulos, M. A., Kastritis, E., Rosinol, L., Bladé, J. & Ludwig, H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22, 1485-1493 (2008).
22. Palumbo, A. et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 23, 87-93 (2009).
23. Rajkumar, S. V. et al. High-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29-37 (2010).
24. Rayner, H. C., Haynes, A. P., Thompson, J. R., Russell, N. & Fletcher, J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q. J. Med. 79, 517-525 (1991).
25. Kumar, S. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21, 2035-2042 (2007). (Pubitemid 47299979)
26. Popat, U. et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol. Blood Marrow Transplant. 15, 718-723 (2009).
27. Kumar, S. et al. International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114, 1729-1735 (2009).
28. Mark, T. et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol. Blood Marrow Transplant. 14, 795-798 (2008). (Pubitemid 351773154)
29. Giralt, S. et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23, 1904-1912 (2009).
30. Palumbo, A. et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract 613]. Blood 114, a253 (2009).